Developer docs
API playgroundTry for free, no card

Search company profiles

LogixX Pharma

Full company profile

uuid002tl9j

Namestring
LogixX Pharma
Legal namestring
LogixX Pharma Limited
Company typeenum
Private
Founded yearint
2010
Descriptiontext

LogixX Pharma is a specialty pharmaceutical company headquartered in Reading, United Kingdom, founded in 2010 by CEO Michael Close. The company acquires marketing and distribution rights to innovative pharmaceutical, medical device, and over-the-counter (OTC) products from partner firms that lack a UK or European presence, and commercializes those products in therapeutic areas characterized by high unmet medical need. Its portfolio spans metabolic and paediatric conditions, male and female fertility and sexual health (the company's stated primary growth segment), and includes named lines Sapropterin LogixX and LogixX Fertility, alongside a broader set of medicinal products and OTCs.

The business is asset-light and licensing-driven rather than R&D or manufacturing-driven, with revenue derived from product commercialization under licensing and royalty arrangements. Distribution is delivered through a B2B partner model across the UK and continental Europe (with partner relationships extending to Italian, German, and US-based firms) and supplemented by a direct Shopify e-commerce storefront. The company relies on a small team (1–10 employees) anchored by a CEO with prior senior roles at Merck Serono, Solvay, and Bayer, and supported since July 2020 by Chief Scientific Advisor Professor Ralf Henkel, whose academic profile includes an h-index of 41 and 167 publications.

Operationally, LogixX Pharma leverages in-house regulatory capability, including Michael Close's MHRA-approved Responsible Person designation, to handle late-phase clinical, registration, and market access activities for in-licensed products. The strategy emphasizes niche, under-served therapeutic conditions, lifecycle management, geographical expansion, and selective product transfers back to originating partners for further commercialization in adjacent areas such as oncology and rare/orphan diseases.

Short descriptiontext

LogixX Pharma is a UK-based specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceuticals, medical devices, and OTCs across Europe, focusing on niche therapeutic areas with high unmet medical need such as fertility and metabolic conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReading, United Kingdom
HQ citystring
Reading
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, pharmaceutical licensing, medical devices distribution, OTC products, rare disease therapeutics
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeLicensing Royalties
Description

LogixX Pharma generates revenue by acquiring rights to market and distribute innovative Pharmaceutical, Medical Device and OTC products. The company focuses on commercializing products in niche therapeutic areas with high unmet medical need.

logixxpharma.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Sapropterin LogixX
Description

Pharmaceutical product for metabolic conditions.

logixxpharma.com
+1 more record
Core offering1 text field

LogixX Pharma is a specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceutical, medical device, and OTC products across the UK and Europe. The company focuses on niche therapeutic conditions with high unmet medical need, particularly in male and female fertility, sexual health, metabolic, and paediatric markets. It provides regulatory, registration, and commercial expertise to partner companies lacking UK market presence.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LogixX Pharma is a speciality pharmaceutical company offering a portfolio of products spanning Pharmaceuticals, Medical Devices, and OTCs. The company operates three named product lines: Sapropterin LogixX (a pharmaceutical for niche therapeutic conditions), LogixX Fertility (focused on male and female fertility and sexual health), and general Medicinal Products. The company acquires rights to market and distribute innovative products in therapeutic areas of high unmet medical need, particularly in metabolic, paediatric, and rare/orphan disease markets.

Product and service4 records
1Sapropterin LogixX
CategorySpecialty Pharmaceutical (Metabolic)
Description

A pharmaceutical product in LogixX Pharma's portfolio targeting niche therapeutic conditions with high unmet medical need, specifically for metabolic conditions.

2LogixX Fertility
CategorySpecialty Pharmaceutical (Fertility and Sexual Health)
Description

A product focused on male and female fertility and sexual health, representing a significant growth area for the company and addressing conditions with high unmet medical need.

3Medicinal Products
CategorySpecialty Pharmaceutical (Metabolic and Paediatric)
Description

Pharmaceutical products acquired for marketing and distribution rights in Europe, focusing on metabolic and paediatric markets with emphasis on novel therapeutics commercialization in niche therapeutic areas.

4Over-the-Counter (OTC) Products
CategoryOTC Consumer Healthcare
Description

Over-the-counter pharmaceutical products within the company's portfolio alongside prescription medicines and medical devices, distributed across therapeutic areas of high unmet medical need.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Alfasigma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-10-01
Description

LogixX Pharma partnered with Alfasigma in October 2013 to support the UK health science business. Michael Close led the partnership activities, providing commercial and regulatory foundation for Alfasigma's products in the UK market. This partnership represents a key strategic relationship for LogixX Pharma in establishing its commercial operations.

logixxpharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

LogixX Pharma has partnered with several Italian, German and US-based startup companies lacking presence in the UK market. The company provides Commercial and Regulatory foundation to support growth of these partners' products in the UK and Europe. Michael Close led these partnership activities, including supporting pharmaceutical product transfers back to originating companies for further commercialization at Group level in oncology and rare/orphan diseases.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chiesi is an Italian-headquartered specialty pharmaceutical group with global presence in rare diseases, respiratory, and neonatology - a profile that mirrors Alfasigma, LogixX's longstanding partner. Comparable through European specialty pharma leadership and rare/orphan disease focus.

TypeDirect peer
Description

Consilient Health is a UK-based specialty pharma company that in-licenses, markets, and distributes prescription pharmaceuticals across niche therapeutic areas. Highly comparable to LogixX in geography (UK/Ireland), business model (licensing/distribution), and therapeutic focus on underserved conditions.

TypeDirect peer
Description

Martindale Pharma (now part of Ethypharm) is a UK specialty pharmaceutical company focused on specialty hospital products, anaesthesia, and addiction treatments. Comparable to LogixX in UK specialty pharma distribution and concentration on niche hospital/specialist channels.

TypeBroad incumbent
Description

Almirall is a European specialty pharmaceutical company with broad dermatology and specialty therapeutic franchises across Europe. Comparable to LogixX in European specialty pharma footprint and in-licensing heritage, though at significantly larger scale and broader portfolio scope.

TypeDirect peer
Description

Norgine is a European specialty pharmaceutical company focused on gastroenterology, hepatology, and rare diseases, with a similar model of in-licensing and commercializing niche therapeutics across European markets. Comparable to LogixX in its European commercialization footprint and niche-therapeutic focus.

TypeDirect peer
Description

Advanz Pharma is a UK-headquartered specialty pharmaceutical company focused on niche/rare disease medicines in Europe. Directly comparable to LogixX in geography (UK base), business model (specialty pharma licensing and commercialization), and therapeutic emphasis on underserved conditions.

TypeDirect peer
Description

SOBI is a European specialty biopharmaceutical company focused on rare diseases. Comparable to LogixX in the rare/orphan disease commercialization focus and European market footprint, though at substantially greater scale.

8Alfasigma
TypeEmerging player
Description

Alfasigma is an Italian specialty pharmaceutical company and LogixX's longest-standing partner (since October 2013). Relevant as both a peer in Italian-headquartered specialty pharma and as the upstream licensor supplying products to LogixX for UK commercialization.

TypeDirect peer
Description

Recordati is an Italian specialty pharmaceutical group with a European presence in rare diseases, cardiovascular, and urology products. Comparable to LogixX through its Italian heritage (similar to Alfasigma partner profile), niche-therapeutic emphasis, and in-licensing/commercialization approach in Europe.

10Shard Speciality Pharma
TypeOthers
Description

Shard Speciality Pharma is a UK specialty pharmaceutical company where LogixX CEO Michael Close serves as a board member. Relevant as an adjacent UK specialty pharma player with shared leadership overlap, providing insight into the broader UK specialty distribution landscape.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LogixX Pharma

Specialty Pharmaceuticalslogixxpharma.co.uk

LogixX Pharma is a UK-based specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceuticals, medical devices, and OTCs across Europe, focusing on niche therapeutic areas with high unmet medical need such as fertility and metabolic conditions.

What LogixX Pharma does

LogixX Pharma is a specialty pharmaceutical company headquartered in Reading, United Kingdom, founded in 2010 by CEO Michael Close. The company acquires marketing and distribution rights to innovative pharmaceutical, medical device, and over-the-counter (OTC) products from partner firms that lack a UK or European presence, and commercializes those products in therapeutic areas characterized by high unmet medical need. Its portfolio spans metabolic and paediatric conditions, male and female fertility and sexual health (the company's stated primary growth segment), and includes named lines Sapropterin LogixX and LogixX Fertility, alongside a broader set of medicinal products and OTCs.

The business is asset-light and licensing-driven rather than R&D or manufacturing-driven, with revenue derived from product commercialization under licensing and royalty arrangements. Distribution is delivered through a B2B partner model across the UK and continental Europe (with partner relationships extending to Italian, German, and US-based firms) and supplemented by a direct Shopify e-commerce storefront. The company relies on a small team (1–10 employees) anchored by a CEO with prior senior roles at Merck Serono, Solvay, and Bayer, and supported since July 2020 by Chief Scientific Advisor Professor Ralf Henkel, whose academic profile includes an h-index of 41 and 167 publications.

Operationally, LogixX Pharma leverages in-house regulatory capability, including Michael Close's MHRA-approved Responsible Person designation, to handle late-phase clinical, registration, and market access activities for in-licensed products. The strategy emphasizes niche, under-served therapeutic conditions, lifecycle management, geographical expansion, and selective product transfers back to originating partners for further commercialization in adjacent areas such as oncology and rare/orphan diseases.

LogixX Pharma firmographics

Firmographics
Name
LogixX Pharma
Legal name
LogixX Pharma Limited
Website
https://logixxpharma.co.uk
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
LogixX Pharma is a UK-based specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceuticals, medical devices, and OTCs across Europe, focusing on niche therapeutic areas with high unmet medical need such as fertility and metabolic conditions.
Ownership category
akta.pro rank

Where LogixX Pharma is headquartered

Location

Headquarters

HQ city
Reading
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

LogixX Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: LogixX Pharma generates revenue by acquiring rights to market and distribute innovative Pharmaceutical, Medical Device and OTC products. The company focuses on commercializing products in niche therapeutic areas with high unmet medical need.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

LogixX Pharma product offering

Product offering

Core offering

LogixX Pharma is a specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceutical, medical device, and OTC products across the UK and Europe. The company focuses on niche therapeutic conditions with high unmet medical need, particularly in male and female fertility, sexual health, metabolic, and paediatric markets. It provides regulatory, registration, and commercial expertise to partner companies lacking UK market presence.

Product overview

LogixX Pharma is a speciality pharmaceutical company offering a portfolio of products spanning Pharmaceuticals, Medical Devices, and OTCs. The company operates three named product lines: Sapropterin LogixX (a pharmaceutical for niche therapeutic conditions), LogixX Fertility (focused on male and female fertility and sexual health), and general Medicinal Products. The company acquires rights to market and distribute innovative products in therapeutic areas of high unmet medical need, particularly in metabolic, paediatric, and rare/orphan disease markets.

Differentiator

Problem solved

Functional benefit

Brands

  • Sapropterin LogixX: Pharmaceutical product for metabolic conditions.
  • LogixX Fertility

Products and services

  • Sapropterin LogixX A pharmaceutical product in LogixX Pharma's portfolio targeting niche therapeutic conditions with high unmet medical need, specifically for metabolic conditions.
  • LogixX Fertility A product focused on male and female fertility and sexual health, representing a significant growth area for the company and addressing conditions with high unmet medical need.
  • Medicinal Products Pharmaceutical products acquired for marketing and distribution rights in Europe, focusing on metabolic and paediatric markets with emphasis on novel therapeutics commercialization in niche therapeutic areas.
  • Over-the-Counter (OTC) Products Over-the-counter pharmaceutical products within the company's portfolio alongside prescription medicines and medical devices, distributed across therapeutic areas of high unmet medical need.

Companies that use LogixX Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

LogixX Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LogixX Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • AlfasigmacoreStrategic or Co-development Partner · 1 October 2013LogixX Pharma partnered with Alfasigma in October 2013 to support the UK health science business. Michael Close led the partnership activities, providing commercial and regulatory foundation for Alfasigma's products in the UK market. This partnership represents a key strategic relationship for LogixX Pharma in establishing its commercial operations.
  • Italian, German and US-based Startup CompaniesminorStrategic or Co-development PartnerLogixX Pharma has partnered with several Italian, German and US-based startup companies lacking presence in the UK market. The company provides Commercial and Regulatory foundation to support growth of these partners' products in the UK and Europe. Michael Close led these partnership activities, including supporting pharmaceutical product transfers back to originating companies for further commercialization at Group level in oncology and rare/orphan diseases.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

LogixX Pharma competitors and assessment

Company assessment

Direct peers

  • Chiesi Farmaceutici: Chiesi is an Italian-headquartered specialty pharmaceutical group with global presence in rare diseases, respiratory, and neonatology - a profile that mirrors Alfasigma, LogixX's longstanding partner. Comparable through European specialty pharma leadership and rare/orphan disease focus.
  • Consilient Health: Consilient Health is a UK-based specialty pharma company that in-licenses, markets, and distributes prescription pharmaceuticals across niche therapeutic areas. Highly comparable to LogixX in geography (UK/Ireland), business model (licensing/distribution), and therapeutic focus on underserved conditions.
  • Martindale Pharma: Martindale Pharma (now part of Ethypharm) is a UK specialty pharmaceutical company focused on specialty hospital products, anaesthesia, and addiction treatments. Comparable to LogixX in UK specialty pharma distribution and concentration on niche hospital/specialist channels.
  • Norgine: Norgine is a European specialty pharmaceutical company focused on gastroenterology, hepatology, and rare diseases, with a similar model of in-licensing and commercializing niche therapeutics across European markets. Comparable to LogixX in its European commercialization footprint and niche-therapeutic focus.
  • Advanz Pharma: Advanz Pharma is a UK-headquartered specialty pharmaceutical company focused on niche/rare disease medicines in Europe. Directly comparable to LogixX in geography (UK base), business model (specialty pharma licensing and commercialization), and therapeutic emphasis on underserved conditions.
  • Swedish Orphan Biovitrum (SOBI): SOBI is a European specialty biopharmaceutical company focused on rare diseases. Comparable to LogixX in the rare/orphan disease commercialization focus and European market footprint, though at substantially greater scale.
  • Recordati: Recordati is an Italian specialty pharmaceutical group with a European presence in rare diseases, cardiovascular, and urology products. Comparable to LogixX through its Italian heritage (similar to Alfasigma partner profile), niche-therapeutic emphasis, and in-licensing/commercialization approach in Europe.

Broad incumbents

  • Almirall: Almirall is a European specialty pharmaceutical company with broad dermatology and specialty therapeutic franchises across Europe. Comparable to LogixX in European specialty pharma footprint and in-licensing heritage, though at significantly larger scale and broader portfolio scope.

Emerging players

  • Alfasigma: Alfasigma is an Italian specialty pharmaceutical company and LogixX's longest-standing partner (since October 2013). Relevant as both a peer in Italian-headquartered specialty pharma and as the upstream licensor supplying products to LogixX for UK commercialization.

Others

  • Shard Speciality Pharma: Shard Speciality Pharma is a UK specialty pharmaceutical company where LogixX CEO Michael Close serves as a board member. Relevant as an adjacent UK specialty pharma player with shared leadership overlap, providing insight into the broader UK specialty distribution landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

LogixX Pharma social profiles

Digital presence

LogixX Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LogixX Pharma leadership team

Management profile

Number of profiles

Profiles2 records

LogixX Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LogixX Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LogixX Pharma

What does LogixX Pharma do?

LogixX Pharma is a specialty pharmaceutical company that acquires rights to market and distribute innovative pharmaceutical, medical device, and OTC products across the UK and Europe. The company focuses on niche therapeutic conditions with high unmet medical need, particularly in male and female fertility, sexual health, metabolic, and paediatric markets. It provides regulatory, registration, and commercial expertise to partner companies lacking UK market presence.

Is LogixX Pharma a public or private company?

LogixX Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was LogixX Pharma founded?

LogixX Pharma was founded in 2010. It employs 11 to 50 people.

Where is LogixX Pharma based?

LogixX Pharma is headquartered in Reading, United Kingdom, in the Europe region.

How does LogixX Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are LogixX Pharma's main competitors?

Direct peers on record are Chiesi Farmaceutici, Consilient Health, Martindale Pharma, Norgine, Advanz Pharma, Swedish Orphan Biovitrum (SOBI) and Recordati. Almirall is listed as a broad incumbent. Alfasigma is listed as an emerging player. Shard Speciality Pharma is listed as an others.

Does LogixX Pharma have an API?

No public API is recorded for LogixX Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals